ClinicalTrials.Veeva

Menu

PK Driven Prophylaxis for Hemophilia A (OBTC)

A

Assistance Publique - Hôpitaux de Paris

Status

Terminated

Conditions

Hemophilia A

Treatments

Device: MyPKFiT

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02634424
P140701

Details and patient eligibility

About

The purpose of this study is to evaluate the implementation of pharmacokinetic (PK) driven prophylaxis in current clinical practice

Full description

Starting from 3 pharmacokinetic (PK) points, data are entered in the PK calculator device, and treatment dose is adjusted following the results of PK values obtained and clinical bleeding data

Enrollment

12 patients

Sex

Male

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male Patient
  • Severe or moderately severe haemophilia A (FVIII = 2 %), preventively treated (processing) by ADVATE for at least 6 months,
  • At last 6 years old,
  • An informed consent must be signed by the patient or his legal representative for the patients minor.
  • Affiliated to a national insurance scheme

Exclusion criteria

  • Previous or actual treatment with FVIII inhibitors > 0,6 UB at the selection
  • Induction of immune tolerance
  • Planned orthopedic surgery for the 18 next months
  • Any other haemostatic pathology
  • Any treatment interacting on the haemostasis
  • Patient under guardianship
  • Patient participating in another biomedical research

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

MyPKFiT
Experimental group
Description:
Personalized prophylaxis : Treatment is adjustment according to PK modeling
Treatment:
Device: MyPKFiT

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems